Company Filing History:
Years Active: 2017
Title: Eri Hashimoto: Innovator in Cancer Therapeutics
Introduction
Eri Hashimoto is a notable inventor based in Kanagawa, Japan. He has made significant contributions to the field of cancer therapeutics through his innovative research and development of antibodies.
Latest Patents
Eri Hashimoto holds a patent for a "Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient." This patent describes the successful production of anti-Epiregulin antibodies that demonstrate cross-species reactivity between cynomolgus monkeys and humans. The antibodies have been engineered to suppress chemical degradation, lower isoelectric points, increase thermal denaturation midpoint temperatures, and reduce aggregation. These advancements enable the antibodies to inhibit the growth of cancer cells by exhibiting cytotoxic and neutralizing activities against human Epiregulin-expressing cancer cells. He has 1 patent to his name.
Career Highlights
Eri Hashimoto is associated with Chugai Seiyaku Kabushiki Kaisha, a prominent company in the pharmaceutical industry. His work focuses on developing innovative solutions for cancer treatment, showcasing his commitment to improving patient outcomes.
Collaborations
Eri has collaborated with notable colleagues, including Hirotake Shiraiwa and Keiko Esaki, who contribute to the research and development efforts in their field.
Conclusion
Eri Hashimoto's contributions to cancer therapeutics through his innovative patent highlight his role as a key inventor in the medical field. His work continues to pave the way for advancements in cancer treatment and patient care.